[HTML][HTML] Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2 …
A Koch, H Watz, MR Maleki-Yazdi, U Bothner… - NPJ Primary Care …, 2017 - nature.com
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist …
A Koch, H Watz, MR Maleki-Yazdi… - Primary Care …, 2017 - search.ebscohost.com
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
[HTML][HTML] Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2 …
A Koch, H Watz, MR Maleki-Yazdi… - NPJ Primary Care …, 2017 - ncbi.nlm.nih.gov
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
[PDF][PDF] Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2 …
A Koch, H Watz, MR Maleki-Yazdi, U Bothner, K Tetzlaff… - core.ac.uk
Bronchodilators, including long-acting β2-agonists (LABAs), are central to the symptom
management of chronic obstructive pulmonary disease (COPD). 1 The twice-daily (BID) …
management of chronic obstructive pulmonary disease (COPD). 1 The twice-daily (BID) …
[PDF][PDF] Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2 …
A Koch, H Watz, MR Maleki-Yazdi, U Bothner, K Tetzlaff… - cyberleninka.org
Bronchodilators, including long-acting β2-agonists (LABAs), are central to the symptom
management of chronic obstructive pulmonary disease (COPD). 1 The twice-daily (BID) …
management of chronic obstructive pulmonary disease (COPD). 1 The twice-daily (BID) …
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2 …
A Koch, H Watz, MR Maleki-Yazdi… - NPJ Primary Care …, 2017 - europepmc.org
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist …
A Koch, H Watz, MR Maleki-Yazdi… - NPJ Primary Care …, 2017 - search.proquest.com
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist …
A Koch, H Watz, MR Maleki-Yazdi, U Bothner, K Tetzlaff… - 2017 - pubmed.ncbi.nlm.nih.gov
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
licensed dose of olodaterol (5 µg once daily [QD] via Respimat® inhaler) in patients with …
Comprehensive assessment of the safety of olodaterol 5 mu g in the Respimat (R) device for maintenance treatment of COPD: comparison with the long-acting beta (2 …
A Koch, H Watz, MR Maleki-Yazdi… - Npj Primary Care …, 2017 - epub.ub.uni-muenchen.de
This analysis provides a comprehensive clinical assessment of the long-term safety of the
licensed dose of olodaterol (5 mu g once daily [QD] via Respimat (R) inhaler) in patients with …
licensed dose of olodaterol (5 mu g once daily [QD] via Respimat (R) inhaler) in patients with …
[PDF][PDF] Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2 …
A Koch, H Watz, MR Maleki-Yazdi, U Bothner, K Tetzlaff… - 2017 - pureadmin.qub.ac.uk
Bronchodilators, including long-acting β2-agonists (LABAs), are central to the symptom
management of chronic obstructive pulmonary disease (COPD). 1 The twice-daily (BID) …
management of chronic obstructive pulmonary disease (COPD). 1 The twice-daily (BID) …